{
  "source": "MFN",
  "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2",
  "retrieved_at": "2026-08-07T01:14:13Z",
  "status": "resolved_no_reports",
  "resolution": {
    "status": "resolved",
    "company_name": "Ascelia Pharma",
    "expected_name": "Ascelia Pharma",
    "match_score": 100.0,
    "slug": "ascelia-pharma",
    "url": "https://mfn.se/all/a/ascelia-pharma",
    "metadata": {
      "country": "Sverige",
      "list": "Small Cap Stockholm",
      "sector": "Hälsovård",
      "industry": "Läkemedel & Handel",
      "website": "https://career.modularfinance.se"
    },
    "ticker_candidates": [],
    "attempts": []
  },
  "releases": [],
  "skipped_because_nasdaq": [
    {
      "report_key": "2026:q1",
      "title": "Kvartalsrapport Q1 2026: Orviglance® närmar sig transformerande milstolpar",
      "date": "2026-05-12",
      "url": "https://mfn.se/a/ascelia-pharma/kvartalsrapport-q1-2026-orviglance-r-narmar-sig-transformerande-milstolpar"
    },
    {
      "report_key": "2025:annual",
      "title": "Årsredovisning 2025: Orviglance NDA inskickad till FDA, PDUFA datum satt till Juli 2026",
      "date": "2026-04-09",
      "url": "https://mfn.se/a/ascelia-pharma/arsredovisning-2025-orviglance-nda-inskickad-till-fda-pdufa-datum-satt-till-juli-2026"
    },
    {
      "report_key": "2025:q4",
      "title": "Full Year and Q4 Report 2025: FDA Accepts Orviglance NDA for Review",
      "date": "2026-02-05",
      "url": "https://mfn.se/a/ascelia-pharma/full-year-and-q4-report-2025-fda-accepts-orviglance-nda-for-review"
    },
    {
      "report_key": "2025:q4",
      "title": "Bokslutskommuniké och Q4 2025: FDA accepterar Orviglance NDA-ansökan för granskning",
      "date": "2026-02-05",
      "url": "https://mfn.se/a/ascelia-pharma/bokslutskommunike-och-q4-2025-fda-accepterar-orviglance-nda-ansokan-for-granskning"
    },
    {
      "report_key": "2025:q3",
      "title": "Delårsrapport Q3 2025: Orviglance NDA-ansökan inskickad till FDA",
      "date": "2025-11-05",
      "url": "https://mfn.se/a/ascelia-pharma/delarsrapport-q3-2025-orviglance-nda-ansokan-inskickad-till-fda"
    }
  ],
  "metadata": {
    "country": "Sverige",
    "list": "Small Cap Stockholm",
    "sector": "Hälsovård",
    "industry": "Läkemedel & Handel",
    "website": "https://career.modularfinance.se"
  },
  "ticker_candidates": [],
  "company_url": "https://mfn.se/all/a/ascelia-pharma",
  "company_text_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\mfn\\company.txt",
  "company_html_path": "D:\\Web\\aktieanalys\\data\\ascelia-pharma\\mfn\\company.html"
}